Recombinant influenza virus encoding a Streptococcus pneumoniae conserved antigen: a bivalent intranasal and intramuscular broad-spectrum vaccine against pneumonia and Flu

IgG antibodies by both routes. In pneumococcal lethal challenges, were observed in vaccine group 65% and 100% protection rates with IN and IM immunization, respectively. The control groups didn’t present relevant protection rates. Since specific antibodies are essential against these pathogens, it’s possible that the high titers of anti-SP IgG antibodies may have contributed to the challenge protection, and that the anti-influenza IgG induced by the intramuscular immunization result in protection against influenza, as already previously observed with intranasal immunization. Conclusion: Thus, these results demonstrate the effectiveness of this vaccine protocol both in intranasal and intramuscular immunization, being, therefore, a promising bivalent broad-spectrum vaccine candidate against pneumonia and Flu.